Cargando…

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience

BACKGROUND: Clinical trials and real-world studies revealed a spectrum of response to CGRP(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at all to total migraine freedom. In this study, we aimed to compare clinical characteristics between super-responders (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raffaelli, Bianca, Fitzek, Mira, Overeem, Lucas H., Storch, Elisabeth, Terhart, Maria, Reuter, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969617/ https://www.ncbi.nlm.nih.gov/pubmed/36843007 http://dx.doi.org/10.1186/s10194-023-01552-x

Ejemplares similares

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Sex Hormones and Calcitonin Gene–Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2022)

Migraine and Hormonal Contraception in Gynecological Outpatient Care—Cross-Sectional Study among Practicing Gynecologists in Germany
por: Fitzek, Mira P., et al.
Publicado: (2023)

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
por: Hong, Ja Bin, et al.
Publicado: (2023)

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021)

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Patients’ and Health Care Workers’ Perception of Migraine Images on the Internet: Cross-sectional Survey Study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
por: Hong, Ja Bin, et al.
Publicado: (2023)

Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
por: Kaltseis, Katharina, et al.
Publicado: (2023)

Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle
por: Raffaelli, Bianca, et al.
Publicado: (2021)

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
por: Waliszewska-Prosół, Marta, et al.
Publicado: (2023)

Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
por: Ashina, Sait, et al.
Publicado: (2023)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one
por: Fresán-Restituto, Daniel, et al.
Publicado: (2023)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment
por: Lombard, Louise, et al.
Publicado: (2020)

CGRPα-Expressing Sensory Neurons Respond to Stimuli that Evoke Sensations of Pain and Itch
por: McCoy, Eric S., et al.
Publicado: (2012)

Identifying “super responders” in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2017)

Defining Responders vs Non-Responders After Total Ankle Arthroplasty
por: Steele, John R., et al.
Publicado: (2019)

A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2020)

Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
por: Vandenbussche, Nicolas, et al.
Publicado: (2023)

Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal
por: Hubbard, Catherine S., et al.
Publicado: (2016)

Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer’s Disease Clinical Trials
por: Wang, Dulin, et al.
Publicado: (2023)

Multiple Receptor Subtypes for the CGRP Super-Family
por: Quirion, R., et al.
Publicado: (2001)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

“Life-changing”: the experience of super-responders to biologics in severe asthma
por: Lanario, Joseph W., et al.
Publicado: (2022)

Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
por: Mavridis, Theodoros, et al.
Publicado: (2021)

The Authors Respond
por: Sherrill, Christina H., et al.
Publicado: (2020)

Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China
por: Zhang, Lei, et al.
Publicado: (2023)

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation
por: Herranz-Pinto, Pedro, et al.
Publicado: (2023)

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
por: Pensato, Umberto, et al.
Publicado: (2022)

Multiple gene aberrations and breast cancer: lessons from super-responders
por: Wheler, Jennifer J., et al.
Publicado: (2015)

Cardiac electrical and mechanical synchrony of super-responders to cardiac resynchronization therapy
por: Li, Ke-Bei, et al.
Publicado: (2020)

Nonischemic Super-Responders in Fusion CRT Pacing with Normal Atrioventricular Conduction
por: Goanță, Emilia-Violeta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u1jn05jjk1661n5mq5nafaqtmd